Avidity Biosciences, Inc.

NasdaqGM RNA

Avidity Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -324.69 M

Avidity Biosciences, Inc. Operating Income is USD -324.69 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -49.44% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Avidity Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -217.27 M, a -32.29% change year over year.
Avidity Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -164.24 M, a -71.44% change year over year.
Avidity Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -95.80 M, a -181.50% change year over year.
Avidity Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -34.03 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: RNA

Avidity Biosciences, Inc.

CEO	Ms. Sarah Boyce
IPO Date	June 12, 2020
Location	United States
Headquarters	10578 Science Center Drive
Employees	253
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Key trends

Past 5 years